Abstract
PurposeThis pooled analysis aims to evaluate the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in lung squamous cell carcinoma with EGFR mutation.MethodsAdvanced stage (IIIB/IV) lung squamous cell carcinoma patients with EGFR mutations treated with EGFR-TKIs were extracted from the publications searched from the databases of EMBASE, Medline (Ovid SP), Web of Science, Cochrane library, PubMed Publisher, ASCO meeting abstract and Google Scholar before August 2016, or identified from the database of Shanghai Chest Hospital from July 2014 to August 2016. Pooled objective response rate, disease control rate and median progression-free survival were accessed directly or by Kaplan-Meier method and combined in different studies by Comprehensive Meta Analysis software via one-group dichotomous or continuous analysis functions.ResultsThe combined objective response rate, disease control rate and median progression-free survival were 31.6% (95%CI, 24.1%∼40.2%), 72.0% (95% CI, 63.5%∼79.2%) and 3.08 months (95% CI, 2.31-3.84 months) in lung squamous cell carcinoma patients with EGFR mutation.ConclusionThe EGFR-TKIs had a modest response for EGFR mutated lung squamous cell carcinoma patients and might be a selective option for those patients.
Highlights
Squamous cell lung cancer accounts for about 25–30% of NSCLC.[1]
The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) had a modest response for EGFR mutated lung squamous cell carcinoma patients and might be a selective option for those patients
One hundred and ten EGFR mutated lung squamous cell carcinoma (LSCC) patients with grouped data in the eight studies were assigned as the first-cohort (Table 1)
Summary
Squamous cell lung cancer accounts for about 25–30% of NSCLC.[1] Progress in the management of advanced lung squamous cell carcinoma (LSCC) has been lagged behind.[2] For example, pemetrexed monotherapy and platinum-based doublet chemotherapy was not approved in patients with squamous histology because of inferior efficacy.[3] bevacizumab, the vascular endothelial growth factor (VEGF) inhibitor, was contraindicated in LSCC due to pulmonary hemorrhage [4,5,6]. The FDA had approved targeted agents as initial treatment for patients with NSCLC, including gefitinib, erlotinib, and afatinib for the patients with EGFR mutations.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
